Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Olema Pharmaceuticals Inc (NASDAQ: OLMA) closed at $12.49 in the last session, up 2.29% from day before closing price of $12.21. In other words, the price has increased by $2.29 from its previous closing price. On the day, 0.91 million shares were traded. OLMA stock price reached its highest trading level at $12.66 during the session, while it also had its lowest trading level at $11.75.
Ratios:
We take a closer look at OLMA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.13 and its Current Ratio is at 9.13. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on April 02, 2024, initiated with a Buy rating and assigned the stock a target price of $24.
On January 30, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $20.
On July 21, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $21.Oppenheimer initiated its Outperform rating on July 21, 2023, with a $21 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 01 ’24 when Paradigm Biocapital Advisors L sold 2,400,000 shares for $14.91 per share. The transaction valued at 35,796,000 led to the insider holds 783,118 shares of the business.
Harmon Cyrus sold 4,066 shares of OLMA for $63,348 on Jul 29 ’24. The Director now owns 752,217 shares after completing the transaction at $15.58 per share. On Jul 30 ’24, another insider, Harmon Cyrus, who serves as the Director of the company, sold 934 shares for $15.55 each. As a result, the insider received 14,524 and left with 751,283 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OLMA now has a Market Capitalization of 715257344 and an Enterprise Value of 477610816.
Stock Price History:
Over the past 52 weeks, OLMA has reached a high of $17.79, while it has fallen to a 52-week low of $8.50. The 50-Day Moving Average of the stock is -3.47%, while the 200-Day Moving Average is calculated to be -0.86%.
Shares Statistics:
According to the various share statistics, OLMA traded on average about 926.31K shares per day over the past 3-months and 599900 shares per day over the past 10 days. A total of 54.99M shares are outstanding, with a floating share count of 49.00M. Insiders hold about 14.43% of the company’s shares, while institutions hold 88.06% stake in the company. Shares short for OLMA as of 1722384000 were 8041839 with a Short Ratio of 8.68, compared to 1719532800 on 6384577. Therefore, it implies a Short% of Shares Outstanding of 8041839 and a Short% of Float of 24.4.
